Biogen's aducanumab

A more controversial/nuanced take on FDA's Alzheimer's disease drug approval

So I see a lot of people debating the merits of $BIIB’s aducanumab drug in light of FDA’s accelerated approval, and the sentiment is largely unidirectional and homogeneous group-think in whatever news outlet you happen to look today. Here I provide a more nuanced and perhaps even controversial take on today’s FDA decision and how I think it’ll impact s…